The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
14
04
2023
received:
07
03
2023
accepted:
30
05
2023
medline:
23
10
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators' consensus as the gold standard. The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.
Substances chimiques
beta 2-Glycoprotein I
0
Autoantibodies
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1702Investigateurs
Medha Barbhaiya
(M)
Karen Costenbader
(K)
Doruk Erkan
(D)
Francis Guillemin
(F)
Alison Hendry
(A)
Florian Manneville
(F)
Ray Naden
(R)
Stephane Zuily
(S)
Mary-Carmen Amigo
(MC)
Tatsuya Atsumi
(T)
Maria Laura Bertolaccini
(ML)
D Ware Branch
(DW)
Guilherme de Jesus
(G)
Katrien M Devreese
(KM)
Camille Frances
(C)
David Garcia
(D)
Steve R Levine
(SR)
Roger A Levy
(RA)
Michael D Lockshin
(MD)
Thomas L Ortel
(TL)
Savino Sciascia
(S)
Maria G Tektonidou
(MG)
Denis Wahl
(D)
Rohan Willis
(R)
Mark Crowther
(M)
Casini Alessandro
(C)
Danieli Andrade
(D)
Laura Andreoli
(L)
Bahar Artim-Esen
(B)
Tadej Avcin
(T)
Michael H Belmont
(MH)
Graziela Carvalheiras
(G)
Ricard Cervera
(R)
Nathalie Costedoat-Chalumeau
(N)
Ali Duarte-Garcia
(A)
Sheetal Desai
(S)
Maria De Sancho
(M)
Reyhan Diz-Kucukkaya
(R)
Aurelien Delluc
(A)
Jean-Christophe Gris
(JC)
Natasha Jordan
(N)
Rebecca K Leaf
(RK)
Jason S Knight
(JS)
Carl Laskin
(C)
Alfred I Lee
(AI)
Kimberly Legault
(K)
Nina Kello
(N)
Maarten Limper
(M)
Karoline Mayer-Pickel
(K)
Pier Luigi Meroni
(PL)
Jack Musial
(J)
Giovanni Orsolini
(G)
Vittorio Pengo
(V)
Michelle Petri
(M)
Guillermo Pons-Estel
(G)
Quentin Raimboug
(Q)
Jose A Gomez Puerta
(JA)
Giovanni Sanna
(G)
Surya V Seshan
(SV)
Angela Tincani
(A)
Cecile Yelnik
(C)
Catherine Zuily
(C)
Zahir Amoura
(Z)
Hannah Cohen
(H)
Robert Roubey
(R)
Nancy Agmon-Levin
(N)
Cassyanne Aguilar
(C)
Paula Alba
(P)
Oral Alpan
(O)
Ales Ambrozic
(A)
Luis Andrade
(L)
Simone Appenzeller
(S)
Yackov Berkun
(Y)
Antonio Cabral
(A)
Guillame Canaud
(G)
Pojen Chen
(P)
Cecilia Chighizola
(C)
Rolando Cimaz
(R)
Maria Jose Cuadrado
(MJ)
Philip G de Groot
(PG)
Philippe de Moerloose
(P)
Ronald Derksen
(R)
Thomas Dörner
(T)
Paul Fortin
(P)
Bill Giannakopoulos
(B)
Emilio B Gonzalez
(EB)
Murat Inanc
(M)
Gili Kenet
(G)
Munther Khamashta
(M)
Martin Kriegel
(M)
Steven Krilis
(S)
Danyal Ladha
(D)
Patti Massicotte
(P)
Gale McCarty
(G)
Jamal Mikdashi
(J)
Barry Myones
(B)
Lisa Sammaritano
(L)
Flavio Signorelli
(F)
Arzu Soybilgic
(A)
Scott Woller
(S)
Ray Zuo
(R)
Informations de copyright
© 2023 American College of Rheumatology.
Références
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol 1999;42:1309-11.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295-306.
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-21.
Sciascia S, Radin M, Cecchi I, et al. 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus 2021;30:1314-26.
Erkan D, Derksen R, Levy R, et al. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus 2011;20:219-24.
Johnson SR, Goek ON, Singh-Grewal D, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheumatol 2007;57:1119-33.
Barbhaiya M, Abreu M, Amigo M, et al. Development of new international classification criteria for antiphospholipid syndrome: needs assessment assay [abstract]. Lupus 2016;25 Suppl:67.
Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken) 2021;73:1490-501.
Bobba RS, Johnson SR, Davis AM. A review of the Sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised Sapporo criteria add value? J Rheumatol 2007;34:1522-7.
Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72:7-19.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400-12.
Schmajuk G, Hoyer BF, Aringer M, et al, SLE classification criteria steering committee and the international SLE expert panel of the initiative. Multicenter Delphi exercise to identify important key items for classifying systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2018;70:1488-94.
Mosca M, Costenbader KH, Johnson SR, et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol 2019;71:91-8.
Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:358-67.
Johnson SR, Khanna D, Daikh D, et al. Use of consensus methodology to determine candidate items for systemic lupus erythematosus classification criteria. J Rheumatol 2019;46:721-6.
Touma Z, Cervera R, Brinks R, et al. Associations between classification criteria items in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2020;72:1820-6.
Tedeschi SK, Johnson SR, Boumpas DT, et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:634-40.
Johnson SR, Naden RP, Fransen J, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol 2014;67:706-14.
Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011;124:215-24.
Chock YP, Moulinet T, Dufrost V, et al. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2019;18:102395.
Bernardoff I, Picq A, Loiseau P, et al. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2022;21:102913.
Loiseau P, Foret T, DeFilippis EM, et al. Risk of livedo reticularis with antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 2022;31:1595-605.
Domingues V, Chock YP, Risse J, et al. Increased risk of acute and chronic renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2022;21:103158.
Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res (Hoboken) 2018;70:571-81.
Fransen J, Johnson SR, van den Hoogen F, et al. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012;64:351-7.
Devreese KM, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020;18:2828-39.
Devignes J, Smaïl-Tabbone M, Hervé A, et al. Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: association with baseline antiphospholipid antibodies titres. Int J Lab Hematol 2019;41:726-30.
McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226-32.
Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of new international classification criteria for antiphospholipid syndrome: phase III case collection results [abstract]. Arthritis Rheumatol 2020; 72 Suppl 10. URL: https://acrabstracts.org/abstract/development-of-new-international-classification-criteria-for-antiphospholipid-syndrome-phase-iii-case-collection-results/.
Sevim E, Zisa D, Andrade D, et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository. Arthritis Care Res (Hoboken) 2022;74:324-35.
Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891-7.
Vandevelde A, Chayoua W, de Laat B, et al. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 2022;20:508-24.
Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol 1995;9:253-66.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
Amarenco P, Bogousslavsky J, Caplan LR, ET AL. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis 2013;36:1-5.
Barbhaiya M, Taghavi M, Zuily S, et al. Development of new antiphospholipid syndrome classification criteria: renal pathology subcommittee report on the characterization of antiphospholipid antibody nephropathy. J Rheumatol 2023. Epub ahead of print.
Puntmann VO, Valbuena S, Hinojar R, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I-analytical validation and clinical qualification. J Cardiovasc Magn Reson 2018;20:67.
Gestational hypertension and preeclampsia. ACOG Practice Bulletin Number 222. Obstet Gyneol 2020;135:e237-60.
Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 2015;14:446-71.
Reményi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease-an evidence-based guideline. Nat Rev Cardiol 2012;9:297-309.
Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2019;32:1-64.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323.